Therefore, further in vivo studies and comprehensive long-term safety assessments are imperative to fully evaluate the risk–benefit profile of inhibiting the PRMT7-SOX9 axis in NSCLC. This evidence concerns the gene SOX9 and non-small cell lung carcinoma.